Facility’s right medicine for startups
Print Edition
GERMANY’S Boehringer Ingelheim yesterday launched the first phase of its 70-million-euro (US$77 million) biopharma manufacturing site in Zhangjiang High-Tech Park in Shanghai, the first of its kind set up by a multinational pharma company in China.
The facility aims to bolster the manufacturing capability and serve innovative drug startups or companies that are not capable of setting up their own manufacturing plants.
The joint venture with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co is also expected to enhance the competitiveness of China’s biopharma industry.
Boehringer Ingelheim has been selected as one of the first companies to be included in China’s biopharma contract manufacturing organization pilot project that allows domestic and overseas drug companies to outsource their manufacturing and early-phase R&D work to eligible third parties.
The new facility in Shanghai, the company’s fourth after those in Germany, Austria and the United States, is key to improving its global manufacturing network.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
